Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T18867 |
Val-Cit-PAB-MMAE
|
||
Val-Cit-PAB-MMAE 是 ADC 的药物-接头偶联物。它包含 ADC 接头(肽 Val-Cit-PAB)和有效的微管蛋白抑制剂 MMAE。 | |||
T17983 |
Fmoc-Val-Cit-PAB-MMAE
|
Others | Others |
Fmoc-Val-Cit-PAB-MMAE 由 ADC 接头 (Fmoc-Val-Cit-PAB) 和强效微管蛋白抑制剂 (MMAE) 组成。 它是一种用于 ADC 的药物-接头偶联物。 | |||
T39307 |
Azido-PEG4-Val-Cit-PAB-MMAE
Azido-PEG4-Val-Cit-PAB-MMAE |
||
Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor), connected through the cleavable linker Azido-PEG4-Val-Cit-PAB-OH. | |||
T18736 |
SuO-Val-Cit-PAB-MMAE
|
Others | Others |
SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker comprising the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the SuO-Val-Cit-PAB peptide. | |||
T18299 |
Mal-PEG8-Val-Cit-PAB-MMAE
|
Others | Others |
Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. | |||
T39328 |
SuO-Glu-Val-Cit-PAB-MMAE
|
||
SuO-Glu-Val-Cit-PAB-MMAE is a chemical compound comprising a cleavable ADC linker, SuO-Glu-Val-Cit-PAB, and a potent tubulin inhibitor known as MMAE. It is utilized in the synthesis of antibody-drug conjugates (ADCs). | |||
T77876 |
Py-MAA-Val-Cit-PAB-MMAE
AAJ8D6-PY-Val-Cit-MMAE |
||
Py-MAA-Val-Cit-PAB-MMAE (AAJ8D6-PY-Val-Cit-MMAE) 是一款ADC Linker,专用于合成抗体药物偶联物Zapadcine-3a (ADC)。Zapadcine-3a 对抗多种肿瘤表现出高效的活性,其作用机理为定位TRAILR2并通过肿瘤细胞内的溶酶体被摄取,进而针对性释放致死的小分子,从而特异性消灭TRAILR2阳性的肿瘤细胞,并能够有效地治愈肿瘤。 | |||
T17435 |
Amino-PEG4-Val-Cit-PAB-MMAE
|
Others | Others |
Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker employed in the synthesis of ADCs[1]. | |||
T17938 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE
|
Others | Others |
Endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable four-unit polyethylene glycol (PEG) linker, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1]. | |||
T18250 |
MAL-di-EG-Val-Cit-PAB-MMAE
|
Others | Others |
MAL-di-EG-Val-Cit-PAB-MMAE comprises the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, which are essential components of antibody-drug conjugates (ADCs). | |||
T81361 |
PSMA-Val-Cit-PAB-MMAE
|
||
PSMA-Val-Cit-PAB-MMAE是一种靶向前列腺特异性膜抗原(PSMA)的小分子化合物,用MMAE作为药效基团进行前列腺癌治疗。 | |||
T67428 | mDPR-Val-Cit-PAB-MMAE | ||
mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate. | |||
T77866 |
OH-Glu-Val-Cit-PAB-MMAE
|
||
OH-Glu-Val-Cit-PAB-MMAE 是由可切割的 ADC 连接子 (OH-Glu-Val-Cit-PAB) 与有效的微管蛋白抑制剂 (MMAE) 构成,适用于抗体-活性分子偶联物 (ADC) 的合成。 | |||
T77885 |
(Aminooxy)acetamide-Val-Cit-PAB-MMAE
|
||
'(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) 是用于ADC药物-接头偶联物合成的中间体。该化合物通过与聚酰胺形成肟键,得到MMAE聚酰胺偶联物,进一步与Trastuzumab偶联,制备成ADC。' | |||
T18321 |
Mc-Val-Cit-PAB-Cl
|
Others | Others |
Mc-Val-Cit-PAB-Cl 是一种可切割的 ADC 接头,可用于偶联 MMAE 和抗体以形成抗体-MC-vc-MMAE。 | |||
T77839 |
Bi-Mc-VC-PAB-MMAE
|
||
Bi-Mc-VC-PAB-MMAE是由ADC linker (Fmoc-Val-Cit-PAB) 与MMAE构成,后者为一种有效的(tubulin)抑制剂,用于偶联抗体。 | |||
T80884 | Val-Cit-amide-Ph-Maytansine | ||
Val-Cit-amide-Ph-Maytansine 是用于肝细胞生长因子受体 c-Met (MET) 或抗体药物偶联物 (ADCs) 的抗体和双特异性抗原结合分子。 | |||
T77892 |
Mal-PEG8-Val-Cit-PAB-MMAF
|
||
Mal-PEG8-Val-Cit-PAB-MMAF 是一种用于抗体药物偶联体 (ADC) 的药物-连接物复合体 (drug-linker conjugate for ADC)。该化合物由一个可降解的 ADC linker 以及有效的微管蛋白抑制剂 MMAE 组成。 |